SUO Annual Meeting 2021
Society of Urologic Oncology 22nd Annual Meeting
Advertisement
Active surveillance, standard of care for low-risk prostate cancer, may be safe for patients with intermediate-risk disease.
Researchers evaluate PSA screening frequency and the effect of different screening intensities on prostate cancer diagnoses.
The CxBladder Monitor urine test is feasible and safe for patients on surveillance for NMIBC, results of a pilot study ...
Urologists contribute the most to Medicare Part D medication costs, likely because of high-cost urologic cancer care meds.
Researchers used a natural language processing method to analyze kidney function inclusion criteria for a clinical trial.
Researchers observed treatment for MIBC in academic facilities didn’t mitigate poorer outcomes for disadvantaged ...
Researchers evaluated the new AUA risk stratification system for survival in patients with clear cell or papillary RCC.
177Lu-PSMA-I&T followed by radical prostatectomy with PLND appeared safe in patients with high-risk prostate cancer.
For prostate cancer patients, variables like definitive treatment and time to treatment initiation are inferior at HSDPs.
Researchers identified survival predictors in patients with renal cell carcinoma with inferior vena cava thrombus.
Cost analysis was used to evaluate whether transperineal prostate biopsy is superior to standard transrectal prostate biopsy.
Active surveillance doesn’t result in inferior renal function compared with partial nephrectomy in patients with ...
Advertisement
670 Madison Ave.
Manalapan, NJ 07726